Breaking new ground to advance science with the potential to change lives
Beam Therapeutics is a clinical-stage biotech company pioneering base editing technology to develop precision genetic medicines. Their platform uses proprietary base editors delivered via nonviral, electroporation, and viral modalities to correct disease-causing mutations in DNA. The company's pipeline targets serious diseases including sickle cell disease, phenylketonuria, and alpha-1 antitrypsin deficiency.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
May 2024
Feb 2020
Mar 2019
May 2018
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
